keyword
MENU ▼
Read by QxMD icon Read
search

Non-small cell lung cancer side effects

keyword
https://www.readbyqxmd.com/read/28812120/risk-adapted-robotic-stereotactic-body-radiation-therapy-for-inoperable-early-stage-non-small-cell-lung-cancer
#1
Susanne Temming, Martin Kocher, Erich Stoelben, Lars Hagmeyer, De-Hua Chang, Konrad Frank, Khosro Hekmat, Juergen Wolf, Wolfgang W Baus, Robert Semrau, Christian Baues, S Marnitz
PURPOSE: To evaluate efficacy and toxicity of stereotactic body radiation therapy (SBRT) with CyberKnife® (Accuray, Sunnyvale, CA, USA) in a selected cohort of primary, medically inoperable early-stage non-small cell lung cancer (NSCLC) patients. METHODS: From 2012 to 2016, 106 patients (median age 74 years, range 50-94 years) with primary NSCLC were treated with SBRT using CyberKnife®. Histologic confirmation was available in 87 patients (82%). For mediastinal staging, 92 patients (87%) underwent (18)F-fluorodeoxyglucose positron-emission tomography (18-FDG-PET) and/or endobronchial ultrasound (EBUS)-guided lymph node biopsy or mediastinoscopy...
August 15, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28809468/construction-of-supramolecular-drug-drug-delivery-system-for-non-small-cell-lung-cancer-therapy
#2
Zhihao Zhang, Leilei Shi, Chenwei Wu, Yue Su, Jiwen Qian, Hongping Deng, Xinyuan Zhu
Nanoscale drug delivery systems (DDSs) are generally considered to be an effective alternative to small molecular chemotherapeutics due to the improved accumulation in tumor site and enhanced retention in blood. Nevertheless, most of DDSs have low loading efficiency or even pose high threat to normal organs caused by severe side effects. Ideally, supramolecular drug-drug delivery system (SDDDS) made up of pure drugs via supramolecular interaction provides a hopeful solution for cancer treatment. Herein, we put forward a facile method to construct SDDDS via co-assembly of Gefitinib (GEF) and tripeptide tyroservatide (YSV), two kinds of chemotherapeutic pharmaceuticals for non-small cell lung cancer (NSCLC), via multiple intermolecular interactions, including hydrogen bond and π-π stacking...
August 15, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28794371/successful-treatment-with-alectinib-for-choroidal-metastasis-in-anaplastic-lymphoma-kinase-rearranged-non-small-cell-lung-cancer
#3
Tomoko Funazo, Kyohei Morita, Naoya Ikegami, Chisato Konishi, Satoshi Nakao, Ryo Ariyasu, Masato Taki, Kazuhiko Nakagawa, Moon Hee Hwang, Chie Yoshimura, Toshiaki Wakayama, Yasuo Nishizaka
Choroidal metastasis is rare in cancer patients and it may cause visual disturbances that reduce their quality of life. In non-small cell lung cancer (NSCLC), targeted therapy against actionable driver mutations has gradually replaced radiotherapy as the treatment of choice for choroidal metastasis. Recently, there have been several case reports of choroidal metastasis in patients with anaplastic lymphoma kinase (ALK)-rearranged NSCLC. We herein report the case of a 40-year-old Japanese woman diagnosed with choroidal metastasis of an ALK-rearranged NSCLC who received alectinib as the first-line chemotherapy...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28769793/in-metastatic-non-small-cell-lung-cancer-platinum-based-treated-patients-herbal-treatment-improves-the-quality-of-life-a-prospective-randomized-controlled-clinical-trial
#4
Huiru Guo, Jia X Liu, Hegen Li, Jan P A Baak
Background: According to clinical experience, Traditional Chinese Medicine (TCM) herbs added to platinum-based therapy (PBT) improve the Quality of Life (QOL) in metastatic non-small cell lung cancer (NSCLC) patients, but this must be prospectively validated. Patients and Methods: Based on clinical impressions regarding the effect of adding TCM herbs to platinum-based chemotherapy, we anticipated that 2 × 21 patients would be sufficient to obtain significant results with an α < 0.05 and power (1 - β) of 90%...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28760151/pureair-protocol-randomized-controlled-trial-of-intensive-pulmonary-rehabilitation-versus-standard-care-in-patients-undergoing-surgical-resection-for-lung-cancer
#5
Stefania Fugazzaro, Stefania Costi, Carlotta Mainini, Besa Kopliku, Cristian Rapicetta, Roberto Piro, Roberta Bardelli, Patricia Filipa Sobral Rebelo, Carla Galeone, Giorgio Sgarbi, Filippo Lococo, Massimiliano Paci, Tommaso Ricchetti, Silvio Cavuto, Domenico Franco Merlo, Sara Tenconi
BACKGROUND: Non-small cell lung cancer is the most common type of lung cancer. Surgery is proven to be the most effective treatment in early stages, despite its potential impact on quality of life. Pulmonary rehabilitation, either before or after surgery, is associated with reduced morbidity related symptoms and improved exercise capacity, lung function and quality of life. METHODS: We describe the study protocol for the open-label randomized controlled trial we are conducting on patients affected by primary lung cancer (stages I-II) eligible for surgical treatment...
July 31, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28760000/cholesterol-derivative-based-liposomes-for-gemcitabine-delivery-preparation-in-vitro-and-in-vivo-characterization
#6
Tang Li, Li Chen, Yihui Deng, Xinrong Liu, Xiaoyun Zhao, Yiwen Cui, Jia Shi, Rui Feng, Yanzhi Song
As an anti-tumor drug, gemcitabine (Gem) is commonly used for the treatment of non-small cell lung cancer and pancreatic cancer. However, there are several clinical drawbacks to using Gem, including its extremely short plasma half-life and side effects. To prolong its half-life and reduce its side effects, we synthesized a derivative of Gem using cholesterol (Chol). This derivative, called gemcitabine-cholesterol (Gem-Chol) was entrapped into liposomes by a thin-film dispersion method. The particle size of the Gem-Chol liposomes was 112...
August 1, 2017: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/28750665/renal-damage-induced-by-pemetrexed-causing-drug-discontinuation-a-case-report-and-review-of-the-literature
#7
Yassir Sbitti, Hafsa Chahdi, Khaoula Slimani, Adil Debbagh, Anouar Mokhlis, Abderrahmane Albouzidi, Fahd Bennani, Hassan Errihani, Mohamed Ichou
BACKGROUND: Pemetrexed maintenance therapy holds tremendous potential in improving the survival of patients with advanced pulmonary adenocarcinoma. Major side effects include myelosuppression and cutaneous reactions. However, little data are available on pemetrexed nephrotoxicity. Our case describes clinically relevant renal events leading to treatment discontinuation in routine practice. CASE PRESENTATION: We report a case of a 69-year-old Moroccan man treated for metastatic non-small cell lung cancer...
July 28, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28744168/spotlight-on-ramucirumab-in-the-treatment-of-nonsmall-cell-lung-cancer-design-development-and-clinical-activity
#8
REVIEW
Manuel Cobo, Vanesa Gutiérrez, Rosa Villatoro, Jose Manuel Trigo, Inmaculada Ramos, Omar López, María Ruiz, Ana Godoy, Irene López, Macarena Arroyo
The vascular endothelial growth factor (VEGF) and receptor is a therapeutic target because of the importance of this pathway in carcinogenesis. This pathway regulates and promotes angiogenesis as well as increases endothelial cell proliferation, permeability, and cancer survival. Ramucirumab is a new fully human monoclonal antibody that targets the VEGF receptor-2, an important key receptor implicated in angiogenesis. Ramucirumab has been approved for the treatment of second-line advanced or metastatic non-small cell lung cancer (NSCLC) in combination with the chemotherapy agent docetaxel...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28739776/phase-ii-study-of-the-efficacy-and-safety-of-high-dose-pemetrexed-in-combination-with-cisplatin-versus-temozolomide-for-the-treatment-of-non-small-cell-lung-cancer-with-brain-metastases
#9
MULTICENTER STUDY
Qiaowei He, Xizhuang Bi, Chao Ren, Yong Wang, Peng Zou, Hongtao Zhang, Nan Chi, Chunming Xiu, Yunbo Wang, Rongjie Tao
The aim of this study was to explore the efficacy and safety of high-dose pemetrexed with cisplatin versus combination with temozolomide in patients with brain metastases (BM) of lung adenocarcinoma. After standard whole-brain radiotherapy (WBRT, 30 Gy/10 fractions), patients with BM of non-small cell lung cancer (NSCLC) were given high-dose pemetrexed (900 mg/m(2)) on day 1 of each cycle (3 weeks), and cisplatin was administered on days 1-3 in the cisplatin-treated group. The temozolomide-treated group was treated as follows: 75 mg/m(2) temozolomide orally with concurrent WBRT followed by 150 mg/m(2) temozolomide on days 1-5 with high-dose pemetrexed (900 mg/m(2)) on day 1 of each cycle (3 weeks)...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28738964/-clinical-research-on-albumin-bound-paclitaxel-based-therapy-in-advanced-lung-cancer
#10
Xu Li, Bin Ai, Ping Zhang, Lin Li, Xiaonan Wu
BACKGROUND: Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA) to improve the efficacy of paclitaxel and reduce its adverse reactions. The aim of this retrospective study is to observe the efficacy and safety of albumin-bound paclitaxel-based therapy in the treatment of lung cancer. METHODS: We have enrolled 50 patients with advanced or unresectable retreatment lung cancer who were admitted from November 2011 to December 2014...
July 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28718011/case-series-on-the-association-between-blood-levels-and-side-effects-of-afatinib-maleate
#11
Junya Sato, Naoto Morikawa, Ryosuke Chiba, Satoru Nihei, Satoshi Moriguchi, Heisuke Saito, Kohei Yamauchi, Kenzo Kudo
PURPOSE: Afatinib maleate (AFA) is a second-generation, tyrosine kinase inhibitor (TKI) treatment for specific variants of non-small cell lung cancer exhibiting epidermal growth factor receptor (EGFR) mutations. In this study, we measured the blood AFA levels in six patients with lung cancer and investigated the association between blood levels and side effects of this drug. METHODS: The study subjects were patients who were administered AFA for non-small cell lung cancer...
July 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28710963/2-substituted-3-7-8-trimethylnaphtho-1-2-b-furan-4-5-diones-as-specific-l-shaped-nqo1-mediated-redox-modulators-for-the-treatment-of-non-small-cell-lung-cancer
#12
Xiaojin Zhang, Jinlei Bian, Xiang Li, Xingsen Wu, Yanan Dong, Qidong You
Based on the scaffold of 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-dione, a series of L-shaped derivatives with substituted side chains at the position of C2 were designed by analyzing the binding mode with NQO1. The drug-like compound 6q (named as DDO-7178) emerged as the most specific substrate of the two-electron oxidoreductase NQO1 and could hardly be reduced by one-electron oxidoreductases CPR (NQO1/CPR = 20.8). In addition, compound 6q showed much improved physicochemical properties such as water solubility than the control β-lap...
June 15, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28690518/trichoscopic-findings-of-erosive-pustular-dermatosis-of-the-scalp-associated-with-gefitinib
#13
Tomohisa Fukui, Hideo Kitamura, Ken Harada, Hajime Nakano, Daisuke Sawamura
Alopecia associated with epidermal growth factor receptor (EGFR) inhibitor therapy is a rare cutaneous side effect with the potential to progress to scarring alopecia. Thus, dermatologists should make an early diagnosis. We present the case of a 57-year-old Japanese female with scarring alopecia associated with gefitinib, which is an EGFR inhibitor, including trichoscopic findings. The patient treated with gefitinib for non-small cell lung cancer experienced skin rash and hair loss of the scalp. The scalp lesions appeared similar to erosive pustular dermatosis of the scalp...
May 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28673007/cytokine-induced-killer-cell-therapy-for-modulating-regulatory-t-cells-in-patients-with-non-small-cell-lung-cancer
#14
Baodan Yu, Junli Wang, Chen He, Wei Wang, Jianli Tang, Runhui Zheng, Chengzhi Zhou, Huanhuan Zhang, Zhiping Fu, Qiasheng Li, Jun Xu
Previous studies have reported that regulatory T cells (Tregs), which are physiologically engaged in the maintenance of immunological self-tolerance, have a critical role in the regulation of the antitumor immune response. Targeting Tregs has the potential to augment cancer vaccine approaches. The current study therefore aimed to evaluate the role of cytokine-induced killer (CIK) cell infusion in modulating Tregs in patients with non-small cell lung cancer (NSCLC). A total of 15 patients with advanced NSCLC were treated by an infusion of CIK cells derived from autologous peripheral blood mononuclear cells (PBMCs)...
July 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28669346/crizotinib-versus-chemotherapy-on-alk-positive-nsclc-%C3%AF-a-systematic-review-of-efficacy-and-safety
#15
Mingxia Wang, Guanqi Wang, Haiyan Ma, Baoen Shan
Introduction Crizotinib was approved to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) by the Food and Drug Administration in 2011.We conducted a systematic review of clinical trials and retrospective studies to compare the efficacy and safety of crizotinib with chemotherapy. Methods We searched electronic databases from inception to Dec. 2016. Clinical trials and retrospective studies regarding crizotinib and crizotinib versus chemotherapy in treatment of NSCLC were eligible...
June 23, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28666240/myasthenia-gravis-an-emerging-toxicity-of-immune-checkpoint-inhibitors
#16
REVIEW
D Makarious, K Horwood, J I G Coward
The advent of immunotherapy has heralded a number of significant advances in the treatment of particular malignancies associated with poor prognosis (melanoma, non-small-cell lung, renal and head/neck cancers). The success witnessed with therapeutic agents targeting cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 and programmed cell death ligand 1 immune checkpoints has inevitably led to an explosion in their clinical application and the subsequent recognition of specific toxicity profiles distinct from those long recognised with chemotherapy...
September 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28656293/anti-proliferation-and-anti-metastasis-effect-of-barbaloin-in-non-small-cell-lung-cancer-via-inactivating-p38mapk-cdc25b-hsp27-pathway
#17
Zhang Zhang, Wei Rui, Zi-Chen Wang, Da-Xin Liu, Lin Du
Non-small cell lung carcinoma (NSCLC) is the most common lung cancer with high morbidity and mortality. The traditional treatment for NSCLC is particularly liable to relapse with many side-effects. Barbaloin is a natural compound with anticancer efficacy. The present study aimed to investigate the anticancer potential of barbaloin in NSCLC. The results displayed that barbaloin inhibited the viability of A549 cells by decreasing cell growth and the expression level of Ki-67 and proliferating cell nuclear antigen (PCNA), especially at high concentrations (50 and 100 µM)...
June 27, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28640251/inhibition-of-cancer-growth-in-vitro-and-in-vivo-by-a-novel-ros-modulating-agent-with-ability-to-eliminate-stem-like-cancer-cells
#18
Jiankang Wang, Bingling Luo, Xiaobing Li, Wenhua Lu, Jing Yang, Yumin Hu, Peng Huang, Shijun Wen
Reactive oxygen species (ROS) have a crucial role in cell signaling and cellular functions. Mounting evidences suggest that abnormal increase of ROS is often observed in cancer cells and that this biochemical feature can be exploited for selective killing of the malignant cells. A naturally occurring compound phenethyl isothiocyanate (PEITC) has been shown to have promising anticancer activity by modulating intracellular ROS. Here we report a novel synthetic analog of PEITC with superior in vitro and in vivo antitumor effects...
June 22, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28625638/development-of-psoriatic-arthritis-during-nivolumab-therapy-for-metastatic-non-small-cell-lung-cancer-clinical-outcome-analysis-and-review-of-the-literature
#19
Juan Ruiz-Bañobre, Eva Pérez-Pampín, Jorge García-González, Antonio Gómez-Caamaño, Francisco Javier Barón-Duarte, Rafael López-López, Francisca Vázquez-Rivera
Lung cancer is the leading cause of cancer-related death worldwide. The most common type, non-small cell lung cancer (NSCLC), is further divided into two main types, squamous cell and non-squamous cell (which includes adenocarcinoma). Nivolumab, a fully human IgG4 programmed death-1 immune checkpoint inhibitor antibody, has shown not only an overall survival advantage when compared to docetaxel, but also a relatively good side-effect profile among patients with previously treated advanced squamous and non-squamous NSCLC...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28618947/treatment-outcome-comparisons-between-exons-19-and-21-egfr-mutations-for-non-small-cell-lung-cancer-patients-with-malignant-pleural-effusion-after-first-line-and-second-line-tyrosine-kinase-inhibitors
#20
Zhen Zheng, Deyao Xie, Huafang Su, Baochai Lin, Lihao Zhao, Xia Deng, Hanbin Chen, Shaoran Fei, Xiance Jin, Congying Xie
Recent studies demonstrated a significantly increased frequency of epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) patients with malignant pleural effusions (MPEs). The purpose of this study is to investigate the effect of first-line and second-line EGFR-tyrosine kinase inhibitors (TKIs) in the treatment of NSCLC with MPEs harboring exon 19 deletion and L858R mutation. From 2010 to 2015, 203 NSCLC patients with MPEs harboring EGFR mutation treated with EGFR-TKIs were reviewed...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
keyword
keyword
3577
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"